ERBB2 and breast carcinoma: Thirty‐two locally/systemically advanced breast cancers treated with first‐line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically‐analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.